Investors Who Bought Amicus Therapeutics (NASDAQ:FOLD) Shares Three Years Ago Are Now Up 47%

While Amicus Therapeutics, Inc. (NASDAQ:FOLD) shareholders are probably generally happy, the stock hasn’t had particularly good run recently, with the share price falling 19% in the last quarter. But over the last three years returns have been decent. It beat the market return of 41% in that time, gaining 47%.

See our latest analysis for Amicus Therapeutics

Amicus Therapeutics isn’t a profitable company, so it is unlikely we’ll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. That’s because it’s hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

Over the last three years Amicus Therapeutics has grown its revenue at 92% annually. That’s well above most pre-profit companies. While the compound gain of 14% per year over three years is pretty good, you might argue it doesn’t fully reflect the strong revenue growth. So now might be the perfect time to put Amicus Therapeutics on your radar. A window of opportunity may reveal itself with time, if the business can trend to profitability.

NasdaqGM:FOLD Income Statement, September 2nd 2019
NasdaqGM:FOLD Income Statement, September 2nd 2019

Amicus Therapeutics is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. If you are thinking of buying or selling Amicus Therapeutics stock, you should check out this free report showing analyst consensus estimates for future profits.

A Different Perspective

While the broader market gained around 0.9% in the last year, Amicus Therapeutics shareholders lost 27%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 5.8% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. If you would like to research Amicus Therapeutics in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

These great dividend stocks are beating your savings account

Not only have these stocks been reliable dividend payers for the last 10 years but with the yield over 3% they are also easily beating your savings account (let alone the possible capital gains). Click here to see them for FREE on Simply Wall St.